Top 20 pathways associated with the 135 in silico replicated differentially expressed genes after excluding the Finnish experiment
| Pathway | No of differentially expressed genes in the pathway/total no of genes in the pathway | Fisher exact test p value |
| Glucocorticoid receptor signalling | 22/250 | 3.7E–14 |
| IL-17 signalling | 9/70 | 7.0E–08 |
| Pancreatic adenocarcinoma signalling | 10/102 | 1.8E–07 |
| IL-6 signalling | 9/88 | 5.2E–07 |
| IL-2 signalling | 7/52 | 1.5E–06 |
| Phosphatase and Tensin Homolog (PTEN) signalling | 9/101 | 1.7E–06 |
| IL-15 signalling | 7/60 | 4.1E–06 |
| Agrin interactions at neuromuscular junction | 7/60 | 4.1E–06 |
| Tumor Necrosis Factor Receptor 1 (TNFR1) signalling | 6/45 | 9.4E–06 |
| p21-Activated Protein Kinase (PAK) signalling | 7/75 | 1.9E–05 |
| Phosphoinositide 3-Kinase (PI3K)/AKT signalling | 8/108 | 2.5E–05 |
| Regulation of IL-2 expression in activated and anergic T lymphocytes | 7/79 | 2.6E–05 |
| Molecular mechanisms of cancer | 13/303 | 3.0E–05 |
| PPAR signalling | 7/81 | 3.1E–05 |
| Aryl hydrocarbon receptor signalling | 8/115 | 4.0E–05 |
| Role of Janus Kinase 1 (JAK1) and Januse Kinase 3 (JAK3) in γc cytokine signalling | 6/59 | 4.6E–05 |
| Nuclear factor (NF)-κβ signalling | 9/154 | 5.2E–05 |
| Stress-Activated Protein Kinase (SAPK)/c-Jun N-terminal Kinase (JNK) signalling | 7/90 | 6.1E–05 |
| Renal cell carcinoma signalling | 6/64 | 7.3E–05 |
| IL-4 signalling | 6/64 | 7.3E–05 |
IL, interleukin.